Answers are grounded in this paper and cite their sources.
Background Dengue is a rapidly expanding mosquito-borne viral disease that imposes substantial health and economic burdens across endemic regions. Although numerous studies have evaluated the cost of dengue illness and prevention strategies, a comprehensive synthesis integrating economic evidence with longitudinal burden trends remains limited. Methods A systematic review was conducted in accordance with PRISMA 2020 guidelines. Searches of Pubmed, Scopus and Web of Science identified 803 records after the application of database-specific filters, of which 93 studies met the inclusion criteria. Extracted data included direct medical costs, indirect costs, total economic burden, and cost-effectiveness estimates for dengue vaccination and vector-control interventions. To complement the review, country-level disability-adjusted life year (DALY), incidence rates, and death-rate estimates for 15 dengue-endemic countries from 1990 to 2023 were obtained from the Institute for Health Metrics and Evaluation Global Burden of Disease database and analysed using fixed-effects panel regression with robust standard errors. Results Hospitalisation was the principal driver of direct medical costs, with expenditures increasing two- to five-fold in severe dengue cases. Indirect costs, including productivity losses and caregiver time, accounted for 30%–60% of total costs in several studies. National annual economic burden estimates exceeded US$1 billion in highly endemic countries such as India and Brazil, while prior global estimates suggest a worldwide annual burden of approximately US$8.9 billion. Economic evaluations consistently indicated that vaccination and integrated vector-control strategies are cost-effective, particularly in high-transmission settings. In the panel analysis, DALY trajectories exhibited marked heterogeneity across countries, with major surges during epidemic years. Death rate and incidence rates were strongly associated with DALYs. Conclusion Dengue imposes a substantial and persistent economic and health burden, particularly in low- and middle-income countries. Integrating economic evidence with longitudinal burden analysis demonstrates that investments in vaccination, surveillance, and integrated vector management are essential to reduce both health losses and financial hardship in endemic settings.
No takes yet. Share an insight, caveat, or question.
Vats et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: